China has moved a step closer to developing a home-grown mRNA vaccine against Covid-19, with the publication of early trial results for its prime candidate ARCoV.No serious adverse events were recorded in the phase 1 clinical trial data, published last week by The Lancet Microbe, but scientists said it was too early to judge its success.Large-scale trials of the vaccine – jointly developed by the Academy of Military Science, Walvax Biotechnology and Suzhou Abogen Biosciences – have been delayed…South China Morning Post
Related posts
Is Iran war fallout hitting US wholesale prices?
Market Questions is the FT’s guide to the week aheadFinancial TimesChina open to Taiwanese TV and imports after opposition visit
Cheng Li-wun, head of Taiwan’s KMT party, met Chinese President Xi JinpingFinancial TimesTropical Chinese island bids to be world’s largest free-trade hub
Critics ask if biggest economic reforms for decades will pay off for remote provinceFinancial Times